FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib

被引：0
|
作者：
Lixia Gao
Xuli Wang
Yaoliang Tang
Shuang Huang
Chien-An Andy Hu
Yong Teng
机构：
[1] Augusta University,Department of Oral Biology, Dental College of Georgia
[2] University of Utah,Department of Radiology and Imaging Sciences, School of Medicine
[3] University of Utah,Experimental Therapeutics Program, Huntsman Cancer Institute
[4] Augusta University,Vascular Biology Center, Department of Medicine, Medical College of Georgia
[5] University of Florida College of Medicine,Department of Anatomy and Cell Biology
[6] University of New Mexico School of Medicine,Department of Biochemistry and Molecular Biology
[7] Augusta University,Department of Biochemistry and Molecular Biology, Medical College of Georgia
来源：
Journal of Experimental & Clinical Cancer Research | / 36卷
关键词：
FGF19; FGFR4; Hepatocellular carcinoma; Drug resistance; Sorafenib; Synergistic effect;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] RETRACTED: IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells (Retracted Article)
    Li, Yu
    Chen, Gang
    Han, Zhijian
    Cheng, Huijuan
    Qiao, Liang
    Li, Yumin
    ONCOTARGETS AND THERAPY, 2020, 13 : 9721 - 9730
  • [32] Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer
    Chen, Xiaolu
    Liu, Yanan
    Zhang, Liting
    Chen, Daoxing
    Dong, Zhaojun
    Zhao, Chengguang
    Liu, Zhiguo
    Xia, Qinqin
    Wu, Jianzhang
    Chen, Yongheng
    Zheng, Xiaohui
    Cai, Yuepiao
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 214
  • [33] Target immune components to circumvent sorafenib resistance in hepatocellular carcinoma
    Wei, Shuhua
    Wei, Fenghua
    Li, Mengyuan
    Yang, Yuhan
    Zhang, Jingwen
    Li, Chunxiao
    Wang, Junjie
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 163
  • [34] Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma
    Xiao, Hong
    Chen, Hangyu
    Zhang, Lei
    Duolikun, Maimaitiyasen
    Zhen, Baixin
    Kuerban, Subinuer
    Li, Xuehui
    Wang, Yuxi
    Chen, Long
    Lin, Jian
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
  • [35] Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
    Zeng, Zhi
    Lu, Qiliang
    Liu, Yang
    Zhao, Junjun
    Zhang, Qian
    Hu, Linjun
    Shi, Zhan
    Tu, Yifeng
    Xiao, Zunqiang
    Xu, Qiuran
    Huang, Dongsheng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [36] Blocking of FGFR4 signaling by F30 inhibits hepatocellular carcinoma cell proliferation through HMOX1-dependent ferroptosis pathway
    Huang, Fengyu
    Shi, Xueqin
    Hu, Meng
    Yan, Hang
    Li, Xiaohui
    Ding, Yujie
    Zheng, Xinxin
    Cai, Xiaojun
    Dai, Shijie
    Xia, Qinqin
    Cai, Yuepiao
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 970
  • [37] FGFR4 and TGF-β1 Expression in Hepatocellular Carcinoma: Correlation with Clinicopathological Features and Prognosis
    Chen, Zhixin
    Xie, Bao
    Zhu, Qinhua
    Xia, Qinghai
    Jiang, Songmin
    Cao, Ruoyu
    Shi, Lihua
    Qi, Dansi
    Li, Xiaokun
    Cai, Lin
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2013, 10 (13): : 1868 - 1875
  • [38] MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma
    Tomonari, Tetsu
    Takeishi, Shunsaku
    Taniguchi, Tatsuya
    Tanaka, Takahiro
    Tanaka, Hironori
    Fujimoto, Shota
    Kimura, Tetsuo
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Takayama, Tetsuji
    ONCOTARGET, 2016, 7 (06) : 7207 - 7215
  • [39] Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines
    Zhang, Zhi
    He, Cheng-Zu
    Qin, Ya-Qin
    Liao, Jian-Jun
    Huang, Shang-Tao
    Mo, Steven
    Li, Hong-Mian
    Lin, Jian-Yan
    AGING-US, 2020, 12 (23): : 24255 - 24269
  • [40] Mechanisms of sorafenib resistance in hepatocellular carcinoma
    Liang, Yuanjing
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (08)
12345